Blood stem cell products: Toward sustainable benchmarks for clinical translation

摘要: Robust ex vivo expansion of umbilical cord blood (UCB) derived hematopoietic stem and progenitor cells (HSPCs) should enable the widespread use UCB as a source to treat hematologic immune diseases. Novel approaches for HSPC have recently been developed, setting stage production cell products that fulfill our current best known criteria clinical relevance. Translating these technologies into requires bioengineering strategies overcome challenges scale-up, reproducibility, product quality assurance. Clinical-scale implementation also define targets cost-effective manufacturing. As become more effective, new opportunities in therapeutic expanded will emerge. Herein we examine key technological milestones need be met order move therapies from bench-top bedside robust reliable manner.